Cerus Corporation
NASDAQ:CERSMedical - Devices
+$0.08 today
- Market cap
- $391.79M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
Volume 6.09M
Average 2.33M
CERS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cerus CorporationNASDAQ: CERS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $762K, compared with -$5.23M a year earlier. Trailing-twelve-month EBITDA was $1.19M.
Context
- EBITDA amounted to 2.4% of revenue in FY2025, down 3.2 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $5.25M (+206.2%) for the fiscal year ending Dec 2026, a step up from the +50.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $762K-24.3% QoQ
- Last fiscal yearDec 2025
- -$4.94M+50.7% YoY
- LTMMar 2026
- $1.19M+114.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +114.6% | +83.7% | -30.9 pp |
| 1 year | +50.7% | +206.2% | +155.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (4.94M) USD
- Year-over-year change
- +50.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.94M) | +50.7% |
| FY2024 | 2024-12-31 | (10.02M) | +61.9% |
| FY2023 | 2023-12-31 | (26.34M) | +21.4% |
| FY2022 | 2022-12-31 | (33.52M) | +27.1% |
| FY2021 | 2021-12-31 | (45.99M) | — |
EBITDA vs competitors
How CERS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +114.0% is the highest of 4, against a peer median of +6.1%.
- EBITDA amounts to 0.5% of revenue for CERS, versus a peer median of 23.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.75B EUR | +6.1% | +10.8% | 23.5% | |
| LTM Jun 2026 | $261.21M USD | -30.7% | +1.0% | 19.3% | |
| LTM Jun 2026 | $232.99M USD | +42.8% | — | 45.5% | |
| LTM Mar 2026 | $1.19M USD | +114.0% | — | 0.5% | |
| Peer median (excluding CERS) | — | +6.1% | +5.9% | 23.5% | |
Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.86M | 162.05M | 156.37M | 180.27M | 206.13M |
| Cost of Revenue | 63.48M | 74.95M | 69.97M | 80.75M | 95.85M |
| Gross Profit | 67.38M | 87.09M | 86.4M | 99.52M | 110.29M |
| Gross Margin | 51.5% | 53.7% | 55.3% | 55.2% | 53.5% |
| Research & Development | 63.69M | 64.11M | 67.64M | 58.91M | 65.72M |
| Selling, General & Admin | 81.29M | 83.34M | 75.52M | 75.89M | 80.91M |
| Operating Expenses | 116.32M | 121.18M | 116.45M | 113.75M | 146.63M |
| Depreciation & Amortization | 3.15M | 2.98M | 2.6M | 1.86M | 2M |
| EBITDA | (45.99M) | (33.52M) | (26.34M) | (10.02M) | (4.94M) |
| EBITDA Margin | -35.1% | -20.7% | -16.8% | -5.6% | -2.4% |
| Operating Income | (48.94M) | (34.08M) | (30.05M) | (14.23M) | (36.35M) |
| Operating Margin | -37.4% | -21.0% | -19.2% | -7.9% | -17.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.92M | 5.83M | 8.39M | 8.88M | 8.34M |
| Other Income / Expenses | (5.12M) | (8.26M) | (7.27M) | (6.53M) | 21.06M |
| Income Before Tax | (54.06M) | (42.34M) | (37.32M) | (20.76M) | (15.28M) |
| Pre-Tax Margin | -41.3% | -26.1% | -23.9% | -11.5% | -7.4% |
| Income Tax Expense | 319K | 488K | 325K | 205K | 354K |
| Net Income | (54.37M) | (42.78M) | (37.49M) | (20.92M) | (15.63M) |
| Net Margin | -41.6% | -26.4% | -24.0% | -11.6% | -7.6% |
| EPS (Basic) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| EPS (Diluted) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| Weighted Avg Shares | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
| Weighted Avg Shares (Diluted) | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
Cerus Corporation
NASDAQ:CERS
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.